<DOC>
	<DOC>NCT00821093</DOC>
	<brief_summary>This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.</brief_summary>
	<brief_title>Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Adults aged ≥ 40 years Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the GOLD Guidelines, 2007) and: Smoking history of at least 10 pack years Postbronchodilator forced expiratory volume in 1 second (FEV1) &lt; 80% and ≥ 30% of the predicted normal value at screening Postbronchodilator FEV1/FVC (forced vital capacity) &lt; 70% at screening Patients who have received systemic corticosteroids for a COPD exacerbation in the 6 weeks prior to screening or during the runin period Patients requiring longterm oxygen therapy (&gt; 15 h a day) for chronic hypoxemia Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Any patient with active cancer or a history of cancer with less than 5 years diseasefree survival time Patients with a history of long QT syndrome or whose QTc interval (Fridericia's) measured at screening is prolonged Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the runin period Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>respiratory</keyword>
	<keyword>dyspnea</keyword>
	<keyword>breathlessness</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>long-acting β2-agonist</keyword>
</DOC>